MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.
Here’s a quick rundown of a few releases over the past couple days:
Mindray’s sales, profits see double-digit gains
Mindray Medical International Ltd. (NYSE:MR) reported profits of $41.0 million or 35 cents per diluted share, on sales of $211.0 million during the three months ended Dec. 31. That compares with profits of $37.4 million, or 33 cents per diluted share, on sales of $188.8 million during the same period last year.
Full-year profits were $155.5 million, or $1.32 per diluted share, on sales of $704.3 million. That compares with profits of $139.2 million, or $1.23 per diluted share, on sales of $634.2 million in 2009.
Read more
LeMaitre sees earnings quadruple; Q4 outstrips full 2009
LeMaitre Vascular Inc. (NSDQ:LMAT) reported profits of $2.1 million, or 13 cents per diluted share, on sales of $14.4 million during the three months ended Dec. 31. That compares with profits of $1.3 million, or 8 cents per diluted share, on sales of $13.6 million during the same period last year.
Full-year profits were $6.2 million, or 38 cents per diluted share, on sales of $56.1 million. That compares with profits of $1.6 million, or 10 cents per diluted share, on sales of $50.9 million in 2009.
Read more
NuVasive profits rocket
NuVasive Inc. (NYSE:NUVA) reported profits of $61.9 million, or $1.39 per diluted share, on sales of $129.3 million during the three months ended Dec. 31. That compares with a profits of $2.3 million, or 6 cents per diluted share, on sales of $106.9 million during the same period in 2009.
Full-year profits were $78.3 million, or $1.85 per diluted share, on sales of $478.2 million. That compares with profits of $5.8 million, or 15 cents per diluted share, on sales of $370.3 million in 2009.
Read more
Stereotaxis losses ease significantly despite modest revenue growth
Stereotaxis Inc. (NSDQ:STXS) reported losses of $2.5 million, or 5 cents per diluted share, on sales of $14.5 million during the three months ended Dec. 31, 2010. That compares with losses of $6.7 million, or 14 cents per diluted share, on sales of $14.1 million during the same period in 2009.
Full-year losses were $19.9 million, or 39 cents per diluted share, on sales of $54.1 million. That compares with losses of $27.5 million, or 63 cents per diluted share, on sales of $51.1 million in 2009.
Read more
Exactech sales jump 26 percent
Exactech Inc. (NSDQ:EXAC) reported profits of $2.7 million, or 21 cents per diluted share, on sales of $51.8 million during the three months ended Dec. 31, 2010. That compares with profits of about $494,000, or 4 cents per diluted share, on sales of $48.3 million during the same period in 2009.
Full-year profits were $10.5 million, or 80 cents per diluted share, on sales of $190.5 million. That compares with profits of $8.3 million, or 65 cents per diluted share, on sales of $177.3 million in 2009.
Read more
